Evidence map›Paper›PMID 36572800›Full record

SynthesisJournal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing2023

The impact of catheter ablation in patient's heart failure and atrial fibrillation: a meta-analysis of randomized clinical trials.

Ahmed Sayed, Ahmed K Awad, Omar M Abdelfattah, Mahmoud Elsayed, Khader Herzallah, Joseph E Marine, Rod Passman, Jared T Bunch

Abstract readMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Long-term impact of atrial fibrillation catheter ablation on heart failure with preserved ejection fraction.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2025
    Article
  5. Article
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ahmed SayedFaculty of Medicine, Ain Shams University, Cairo, Egypt.ORCID http://orcid.org/0000-0003-0150-8917
Ahmed K AwadFaculty of Medicine, Ain Shams University, Cairo, Egypt.
Omar M AbdelfattahInternal Medicine Department, Morristown Medical Center, Atlantic Health System, Morristown, NJ, USA.
Mahmoud ElsayedSection of Cardiac Electrophysiology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Khader HerzallahDepartment of Cardiology, Tufts Medical Center, Boston, MA, USA.
Joseph E MarineDivision of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Rod PassmanSection of Cardiac Electrophysiology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Jared T BunchDivision of Cardiovascular Medicine, University of Utah Health Sciences Center, 30 North 1900 East, Room 4A100, Salt Lake City, UT, 84132, USA. Jared.Bunch@hsc.utah.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRecent trial data suggest a benefit to catheter ablation (CA) compared to medical therapy for atrial fibrillation (AF) in patients with heart failure (HF). Nevertheless, because of mixed trial evidence, contemporary guidelines give it a class 2 recommendation. Accordingly, we sought to assess the currently available evidence for CA in HF with AF.

methodsElectronic databases were searched to identify randomized clinical trials (RCTs) comparing CA to medical therapy in patients with AF and HF. Study data was pooled using fixed and random effects, and the number needed to treat (NNT) was calculated to gauge absolute risk differences. Heterogeneity was quantified using I

resultsNine trials (CA 1075 patients; medical therapy 1083 patients) were included. Ablation reduced the relative risk of all-cause mortality by 31.5% (95% CI 13.7 to 45.6%; NNT = 23), cardiovascular mortality by 39.3% (95% CI 10.9 to 58.7%; NNT = 31), cardiovascular hospitalization by 29.1% (95% CI 9.4 to 44.6%; NNT = 9), and heart failure hospitalization by 28.5% (95% CI 6.5 to 45.4%; NNT = 22). Improvements in quality of life were observed with CA using the Minnesota Living with Heart Failure Questionnaire (mean difference - 5.26; 95% CI - 2.73 to - 7.78) and the Atrial Fibrillation Effect on Quality of Life (mean difference 5.36; 95% CI 2.72 to 8.00).

conclusionCompared to medical therapy, CA for AF in patients with HF reduces all-cause mortality, cardiovascular mortality, cardiovascular hospitalizations, and heart failure hospitalizations, and may improve quality of life.

Indexed as

Atrial FibrillationCatheter AblationHeart FailureAnti-Arrhythmia AgentsHumansRandomized Controlled Trials as TopicTreatment OutcomeAnti-Arrhythmia AgentsAblationAtrial fibrillationHeart failurePulmonary vein isolationRhythm control

Identifiers

PMID36572800

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.